Also treatment resulted in reduced p-JNK levels in skeletal muscle and liver indicating CNX-013-B2 reduces metabolic stress and hence improves insulin sensitivity (Figure 1I & J).Treatment of ob/ob animals with CNX-013-B2 at 10 mg/kg for 4 weeks improved insulin sensitivity and glucose tolerance resulting in an 18% decrease in glucose AUC (32464 ± 944 vs 26663 ± 1222; p < 0.01) (Figure 2A and B). This evidence concerns the gene MAPK8 and glucose measurement.